CKD-associated pruritus is common in patients receiving dialysis and is linked to impaired sleep, depression, and reduced quality of life. Learn how to identify and manage this condition in clinical practice: ow.ly/xs4r50WLIFh #Dialysis #CKDaP #MedEd

In a 12-week study of patients with moderate-to-severe CKD-aP on hemodialysis, difelikefalin led to clinically meaningful improvements in pruritus and itch-related quality of life. Discover the full results: ow.ly/OiEh50WLIHa #CKDaP #Nephrology

How can we slow kidney function decline in patients with IgA nephropathy? Explore expert perspectives on early diagnosis, proteinuria targets, and the role of combination therapy in IgAN care: ow.ly/KjGl50WPW0r #Nephrology #IgAN #MedicalEducation

Diagnosing and managing ANCA-associated vasculitis can be challenging due to the complexity of the disease. This program offers practical guidance on applying current evidence to improve outcomes. Dive in now: ow.ly/eVk350WPW3Y #AAV #Rheumatology #Nephrology

CKD-associated pruritus (CKD-aP) is more common than many clinicians realize. Recent European data show that over 50% of dialysis patients report some degree of itch, with around 30% experiencing moderate to severe symptoms. Explore the research further: ow.ly/Rnk650WTxiz

Kidneys normally remove extra potassium. In CKD, potassium builds up because the kidneys can’t filter it effectively, raising the risk of hyperkalemia. Learn more about this condition: ow.ly/yp7550WTxmJ #CKD #Electrolytes

Itch in CKD can severely impact sleep, mood, and quality of life. Leading experts discuss tools like the WI-NRS that can help you identify who needs treatment and track improvement over time: ow.ly/MfBr50X1JnK #CKD #MedEd

What does induction therapy look like for patients with ANCA-associated vasculitis? Dr. Hellmich shares how he uses the latest guidelines to tailor treatment based on disease severity and patient needs. Tune in here: ow.ly/Ifwr50X3XvT #Vasculitis #Rheumatology #CME

Among adults on hemodialysis with moderate or severe CKD-associated itch, similar improvements in itch intensity, sleep quality, and QoL were observed after 12 weeks of treatment with a kappa‐opioid receptor agonist. Explore the data further: ow.ly/ifm550X3XBk #Nephrology

Suboptimal RAASi and MRA use in HFrEF and CKD patients is often driven by hyperkalemia risk. This microlearning series breaks down multidisciplinary strategies to optimize therapy. Explore the curriculum: ow.ly/HFK050X3YmT #HeartFailure #CKD #Hyperkalemia #MedEd

In a recent study, IgAN patients on SGLT2i and sparsentan showed sustained reductions in proteinuria (UPCR ↓62% at 14 weeks). eGFR remained stable and no drug-related serious adverse events occurred. Learn more: ow.ly/24x050X3Z9s #IgAN #KidneyHealth #CKD

The updated 2025 KDIGO guidelines for IgA nephropathy are here. Dr. Jürgen Floege breaks down what’s changed, from diagnosis thresholds to treatment strategy. Tune in now: ow.ly/5cWF50X9Lpy #Nephrology #IgAN #KDIGO #MedEd

In a mouse model mimicking human IgAN, sparsentan prevented mesangial proliferation and suppressed key inflammatory pathways, including complement activation and MAPK signaling. Explore the data further: ow.ly/BSjb50X9LvQ #KidneyResearch #IgAN #Glomerulonephritis

Proteinuria is more than a symptom. It's a powerful driver of kidney outcomes in IgA nephropathy (IgAN). Learn how new KDIGO guidelines are reshaping treatment targets and approaches. Listen now: ow.ly/ZLpB50Xb2Pu #Nephrology #IgAN #CME

Dual inhibition of angiotensin II AT1 and endothelin ETA receptors is redefining treatment for chronic progressive kidney disease. Explore how sparsentan delivers on this dual-target strategy: ow.ly/5fXb50Xb3K0 #Nephrology #CKD #IgAN

Hyperkalemia remains a major barrier to continuing life-saving RASi and MRA therapy in CKD. Explore patient-centered ways to manage potassium levels without compromising outcomes: ow.ly/MkHR50Xh5lb #CKD #Hyperkalemia #CardioRenalCare